Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ‐26481585), by the Pediatric Preclinical Testing Program

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|61|2|245-252

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.61, Iss.2, 2014-02, pp. : 245-252

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 6, 2015-06 ,pp. : 1106-1109

John Wiley & Sons Inc

Access to resources Recommend Favorite

Initial testing (stage 1) of the anti‐microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 1545-5009, Iss. 11, 2015-11 ,pp. : 1897-1905

John Wiley & Sons Inc

Access to resources Recommend Favorite

Initial testing (stage 1) of the anti‐microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 11, 2015-11 ,pp. : 1897-1905

John Wiley & Sons Inc

Access to resources Recommend Favorite

Initial testing (Stage 1) of TAK‐701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 61, Iss. 2, 2014-02 ,pp. : 380-382

John Wiley & Sons Inc

Access to resources Recommend Favorite

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 1, 2015-01 ,pp. : 91-98

John Wiley & Sons Inc

Access to resources Recommend Favorite